EUVIMEDEUVIMED entdecken
Crossref

Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity

Xinrong Xiang, Zhengyi Dai, Baozhu Luo, Ninglin Zhao, Song Liu, Jing Sui, Jiasheng Huang, Yuanzheng Zhou, Jinlong Gu, Jiangnan Zhang, Tao Yang iD, Rui Bao iD und 1 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xinrong Xiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Drug Design, Antineoplastic Agents, Leukemia, Myeloid, Acute, Endopeptidase Clp. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The activation of Homo sapiens Casein lysing protease P (HsClpP) by a chemical or genetic strategy has been proved to be a new potential therapy in acute myeloid leukemia (AML). However, limited efficacy has been achieved with classic agonist imipridone ONC201. Here, a novel class of HsClpP agonists is designed and synthesized using a ring-opening strategy based on the lead compound 1 reported in our previous study. Among these novel scaffold agonists, compound 7k exhibited remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 ± 0.03 μM) and antitumor activity in vitro (IC50 = 0.038 ± 0.003 μM). Moreover, the intraperitoneal administration of compound 7k markedly suppressed tumor growth in Mv4-11 xenograft models, achieving a tumor growth inhibition rate of 88%. Concurrently, 7k displayed advantageous pharmacokinetic properties in vivo. This study underscores the promise of compound 7k as a significant HsClpP agonist and an antileukemia drug candidate, warranting further exploration for AML treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignAntineoplastic AgentsLeukemia, Myeloid, AcuteEndopeptidase ClpHumansAnimalsMiceStructure-Activity RelationshipCell Line, TumorXenograft Model Antitumor AssaysCell ProliferationMice, NudeMice, Inbred BALB C

Substanzen

Antineoplastic AgentsEndopeptidase ClpClpP protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Laboratory of Human Diseases and Immunotherapies, West China Hospital and Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University…

ORCID-Profile: Tao Yang, Rui Bao, Youfu Luo

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xiang, X., Dai, Z., Luo, B., Zhao, N., Liu, S., Sui, J., Huang, J., Zhou, Y., Gu, J., Zhang, J., Yang, T., Bao, R., & Luo, Y. (2024). Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00338

Vancouver

Xiang X, Dai Z, Luo B, Zhao N, Liu S, Sui J, et al. Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00338

BibTeX
@article{Xiang2024,
  author = {Xiang, Xinrong and Dai, Zhengyi and Luo, Baozhu and Zhao, Ninglin and Liu, Song and Sui, Jing and Huang, Jiasheng and Zhou, Yuanzheng and Gu, Jinlong and Zhang, Jiangnan and Yang, Tao and Bao, Rui and Luo, Youfu},
  title = {Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00338}
}
Kostenlos starten →